Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2022-09-27 AGM Information
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司关于召开2022年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2022 first extraordinary general meeting (临时股东大会) of 奥锐特药业股份有限公司. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed and voted on, shareholder registration details, and proxy authorization forms. There is no financial data, earnings information, or report content. The document is clearly a meeting notice and not a report or announcement of voting results. It is not a proxy solicitation statement since it does not primarily solicit votes but informs about the meeting and voting procedures. Therefore, the document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the Annual or Extraordinary General Meeting, including notices of meetings.
2022-09-27 Chinese
奥锐特药业股份有限公司第二届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of 奥锐特药业股份有限公司. It details the meeting date, attendance, and specific agenda items such as approval of a restricted stock incentive plan and authorization requests to be submitted to the shareholders' meeting. The document includes voting results and references to further disclosures on the stock exchange website. It does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. It is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is 2713 characters, which is typical for such announcements. Therefore, the classification is MANG with high confidence.
2022-09-27 Chinese
奥锐特药业股份有限公司2022年限制性股票激励计划实施考核管理办法
Remuneration Information Classification · 95% confidence The document is titled as a management method for the implementation and assessment of a 2022 restricted stock incentive plan by 奥锐特药业股份有限公司. It details the purpose, principles, assessment targets, institutions, periods, standards, procedures, and feedback related to the stock incentive plan. There is no financial data, earnings, or audit information presented. It is a policy or governance document related to executive compensation and incentive plans. This fits best under Remuneration Information (DEF 14A), which covers reports detailing compensation and incentive plans for executives and directors. The document length is 2594 characters, which is consistent with a detailed policy document rather than a brief announcement or a full annual report.
2022-09-27 Chinese
奥锐特药业股份有限公司第二届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 9th meeting of the 2nd Supervisory Board of 奥锐特药业股份有限公司. It includes the approval of the company's 2022 semi-annual report and a special report on the use of raised funds. However, the document itself does not contain the full semi-annual report or detailed financial data; instead, it references that the full report and related documents are disclosed elsewhere (in newspapers and on the stock exchange website). The document length is short (1141 characters) and serves as a meeting resolution announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement of meeting resolutions and references to reports, not the report itself.
2022-08-26 Chinese
奥锐特药业股份有限公司2022年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2022 年半年度报告" which translates to "2022 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, company information, financial indicators, and operational details for the period January 1, 2022 to June 30, 2022. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes actual financial statements, management analysis, and comprehensive data typical of an interim or quarterly report. The document explicitly states it is a half-year report and includes financial metrics and management discussion, which fits the definition of an Interim / Quarterly Report (IR). It is not an announcement of a report, nor a full annual report (10-K), nor a regulatory filing or certification. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-26 Chinese
奥锐特药业股份有限公司关于公司2022年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company in 2022, specifically for the half-year period ending June 30, 2022. It includes specifics on the amount raised, usage, balances, and compliance with regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange. The document is titled as a "专项报告" (special report) on the use of raised funds, which aligns with a capital/financing update rather than a full annual or interim financial report. It does not contain comprehensive financial statements or earnings data but focuses on the status and use of fundraising proceeds. The length is under 5,000 characters, but the content is substantive and not merely an announcement of a report. Therefore, it fits best under Capital/Financing Update (CAP).
2022-08-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.